×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Kristie L. Kahl and Andrew Ciupek
Andrew Ciupek, from the GO2 Foundation for Lung Cancer, discusses what is on the horizon for patients with small cell lung cancer.

 
Kristie L. Kahl and Andrew Ciupek
Andrew Ciupek, from the GO2 Foundation for Lung Cancer, talks about the increasing amount of targeted therapies available for patients with non-small cell lung cancer, and why clinical trials are vital in increasing the amount available to those with the disease.
 
Ryan McDonald
The Food and Drug Administration approved Imfinzi in combination with certain standard-of-care chemotherapies in extensive-stage small cell lung cancer, as the therapy improves median overall survival.
 
Katie Kosko
Researchers suggest that patients with advanced non-small cell lung cancer who have limited daily functions should be better educated about therapy decisions.
 
Ryan McDonald
Here is a list of the recent trial initiations that occurred within the cancer space in March.
 
Katie Kosko
Combining immunotherapies with chemotherapy has shown improved survival in patients with extensive-stage small cell lung cancer.
 
Ryan McDonald
Final results of the phase 3 CASPIAN trial show that Imfinzi (durvalumab) in combination with a choice of standard-of-care chemotherapies demonstrates a sustained overall survival benefit in patients with extensive-stage small cell lung cancer.
Kristie L. Kahl
Small cell lung cancer often becomes resistant to chemotherapy, and recent research highlights that these cells evolve, explaining why patients require further lines of treatment.
 
Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Andrew Ciupek, from the Go2 Foundation for Lung Cancer, on the importance of biomarker testing and targeted therapy options for patients with non-small cell lung cancer.
Ryan McDonald
The combination of Keytruda plus chemoradiotherapy induced a ‘promising’ 12-month progression-free survival rate in patients with locally advanced non-small cell lung cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×